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ABSTRACT: Described are photochemical studies of the
nitric oxide precursors, trans-Cr(L)(ONO)2
+ (L = cyclam =
1,4,8,11-tetraazacyclotetradecane, CrONO, or L = mac = 5,7-
dimethyl-6-anthracenylcyclam, mac-CrONO) encapsulated in
phosphatidylcholine liposomes. The liposomes provide a
means to maintain a localized high concentration of NO
releasing complexes and are easily modified for in vivo
targeting through self-assembly. Steady, controlled release of
NO is seen after photolysis of the liposome-encapsulated
CrONO as compared to the burst of NO release seen by the
unencapsulated complex in oxygenated solutions. The quantum yields for photochemical NO release from liposome-
encapsulated CrONO and mac-CrONO were determined in both oxygenated and anoxic solutions. The quantum yield for NO
release in oxygenated solution for encapsulated CrONO was more than 5 times larger than that of unencapsulated CrONO, thus
the net NO released after photolysis in oxygenated solutions is enhanced by encapsulation of CrONO in liposomes.
Encapsulated mac-CrONO shows NO release after photolysis with low-intensity blue light. Furthermore, the fluorescence of
mac-CrONO can be detected through the liposomes, thus allowing for development of theranostic NO delivery vessels where
tracking and imaging can occur simultaneously with therapeutic NO release. This work provides insight into the development of
multifunctional liposome constructs for disease theranostics.
KEYWORDS: nitric oxide release, theranostic, liposomes, photochemical, drug delivery
■ INTRODUCTION
There has long been interest in nitric oxide owing to its
bioregulatory activity in a variety of physiological processes in
both normal and disease states.1,2 The effect of NO is dictated
by its concentration, where nM concentrations lead to
vasorelaxation and higher concentrations up to μM are
responsible for tumor suppression.3−10 NO also acts as a
sensitizer leading to enhanced cell death when generated with
γ-radiation.11−13 For therapeutic NO delivery then, it is critical
to be able to control the concentration of NO released in the
cell. With the intention of designing stimuli responsive NO
releasing complexes for therapeutic applications, we have
developed the NO precursor trans-Cr(cyclam)(ONO)2
+
(“CrONO”, cyclam = 1,4,8,11-tetraazacyclotetradecane, see
the Supporting Information) and related compounds that
release NO only after irradiation with UV or visible light.14−18
Photochemical triggering of such a “caged” bioactive agent
provides the ability to control the timing, dosage, and location
of the NO release by controlling the timing, intensity, and
location of light irradiation.19,20
As shown in Scheme 1, CrONO effectively releases NO with
a high quantum yield after photolysis at 436 nm both in
oxygenated aqueous buffer solutions and in anoxic media
containing the biological reductant glutathione (GSH).17 Such
photolysis-generated NO from CrONO is effective in activating
soluble guanylyl cyclase and in triggering vasodilation in
porcine coronary arterial rings.17 The CrONO complex does
not show any acute toxicity, either alone or with low-intensity
blue light exposure.18 Therefore the CrONO complex is a
promising candidate for the controlled delivery of NO for
therapeutic applications. However it remains a challenge to
deliver the CrONO complexes to targets while maintaining
concentrations that have therapeutic relevance, especially under
in vivo conditions. A highly modular and biocompatible system
employed for drug delivery is liposomes, where therapeutic
materials are easily encapsulated at high concentrations21−25
and targeting capabilities are easily incorporated through the
addition of modified peptides and proteins.26−29 In addition,
the mechanical properties of the liposomes can be tailored to
provide more robust vehicles for delivery of the CrONO
complexes.30 Here, CrONO complexes are encapsulated in
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phosphatidylcholine (PC) liposomes, with the overarching goal
of developing NO releasing theranostic constructs for cancer
therapy and vasodilation: the physiochemical properties of the
resulting structures are studied.
■ EXPERIMENTAL SECTION
Synthesis of trans-Cr(cyclam)(ONO)2BF4 (CrONO).
trans-Cr(cyclam)(Cl)2Cl was synthesized according to pub-
lished procedures by Ferguson31 and Poon et al.32 Cyclam
(1,4,8,11-tetrazacycltetradecane, 98%) was purchased from
Aldrich, and trichlorotris(tetrahydrofuran)chromium(III) was
purchased from Sigma. The trans-Cr(cyclam)(ONO)2BF4 was
prepared from trans-Cr(cyclam)(Cl)2Cl according to a method
slightly modified from that of DeLeo et al.33 Briefly, trans-
Cr(cyclam)(Cl)2Cl (50 mg) was dissolved in deionized H2O
(<5 mL) to which 20 equiv of NaNO2 was added. The purple
solution was refluxed in the dark for 2 h. After reflux, the
resulting orange solution was cooled slightly and NaBF4 was
added. An orange precipitate started to form. The solution was
allowed to cool and precipitate overnight in the fridge. Orange
Cr(cyclam)(ONO)2BF4 was collected by filtration. Crude
product was recrystallized from methanol. Yield: 75%. ESI-
MS: 344.12. UV−vis in water: λmax (ε) 475 (40), 336 (267).
Synthesis of trans-Cr(mac)(ONO)2BF4. trans-Cr(mac)-
(ONO)2BF4 was synthesized according to a previously
published procedure by DeRosa et al.34,35 ESI-MS: 592.
Absorbance and emission spectra are shown in Figure S1 in
the Supporting Information.
Liposome Encapsulation of CrONO and mac-CrONO.
Egg phosphatidylcholine (L-α-phosphatidylcholine, 99%) was
purchased from Avanti Lipids. A phosphatidylcholine (PC) film
was prepared by dissolving 8 mg of PC in CHCl3 in a glass
centrifuge tube and dried under N2 flow. The PC film was
placed overnight in a vacuum oven to remove residual solvent.
The PC film was hydrated with 3 mL of warm (50 °C)
solution, either 10 mM phosphate buffer saline pH 7.4 alone,
buffer with CrONO (1 mM), or buffer with mac-CrONO. The
samples were incubated in a water bath at 50 °C for 10 min and
then vortexed to ensure even hydration. The samples were
frozen in liquid N2 and then thawed to 50 °C in a water bath.
Five cycles were performed to homogenize the PC, and then
the solution was extruded 10× through 100 nm membranes, at
37 °C. The samples were stored refrigerated at 4 °C and
dialyzed in a 50K MWCO membrane against 10 mM PBS (pH
7.4) in the dark. The 10 mM PBS was changed 4× over a 3 day
period. The liposomes (with CrONO and mac-CrONO), final
volume of 3 mL, were stored in the dark at 4 °C until use. The
absorbance and emission spectra of the liposomes with mac-
CrONO are shown in Figure S2 in the Supporting Information.
The size of the liposomes before and after photolysis was
measured using dynamic light scattering. Dynamic light
scattering determined that the liposomes were stable for a
minimum of 2 weeks. At 2 weeks, the constructs with and
without CrONO measured 118 nm and 116 nm, respectively.
For the quantitative NO experiment, the control liposomes
were 138.6 nm in diameter. The liposomes with CrONO were
134.4 nm in diameter. The liposomes with mac-CrONO were
131.9 nm in diameter (Figures S5−S7 in the Supporting
Information).
The concentration of Cr(III) complex in the final stock
solution was determined to be ∼15 μM (see Supporting
Information). This corresponds to ∼0.02 mg of complex
(CrONO MW = 430.92 g/mol, mac-CrONO MW = 562.92 g/
mol) encapsulated in 3 mL. So, using 8 mg of lipid in 3 mL of
PBS, 0.02 mg of the Cr complex can be encapsulated,
corresponding to approximately 1% encapsulation efficiency.
Higher concentrations of lipids can potentially encapsulate
more complex.
Nitric Oxide Detection. Electrode. The NO-specific
electrode was polarized in phosphate buffer for at least 24 h
prior to use. When ready for analysis, the NO electrode was
allowed to equilibrate in 3 mL of 10 mM phosphate buffer
saline pH 7.4 at 25 °C in a quartz cuvette for ∼15 min while
stirring until a stable baseline was reached. At that point the
light (>350 nm selected from a Hg arc lamp) was turned on to
irradiate the sample. Care was taken to ensure the light beam
was below the tip of the electrode in the solution. After 100 s,
an aliquot (200 μL) from the liposome sample stock solution
was injected into the buffer solution. Care was taken to ensure
that the electrode was not bumped when the injection was
made. The current from NO electrode was calibrated by Griess
assay, such that
= − +pA 1307 162[NO]
where the concentration of NO in solution is in nM.
Nitric Oxide Analyzer. Samples of the liposome-encapsu-
lated CrONO and mac-CrONO as well as control liposomes
were prepared in a y-shaped quartz cuvette by dilution of 300
μL of the stock sample into total 3 mL volume of 10 mM PBS
pH 7.4. The sample was placed in a cuvette holder on an optical
train equipped with a 470 nm LED light source (ThorLabs)
and shutter. Helium was bubbled through the sample and into a
Sievers nitric oxide analyzer (NOA 280i). Samples were stirred
and bubbled with either helium or medical grade compressed
air for 3 min in the dark at 25 °C to ensure equilibration. The
samples were then photolyzed for a specific time (30 s, 60 s,
and 90 s), and the NO generated was measured on the NOA.
For total NO release, 100 μL of the stock solution of mac-
CrONO was diluted into 3 mL total volume using 10 mM PBS
pH 7.4. The sample was then photolyzed with the 470 nm LED
until the signal returned to baseline. Integration of the signal
gives a total of 3 nmol of NO released from the 100 μL aliquot.
The NOA is calibrated as instructed in the user manual.
Representative calibration curves are
Scheme 1. Photochemistry of CrONO
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= − ×moles of NO (area 2.6)/6.8 10
for air atmosphere
12
= − ×moles of NO (area 2.6)/5.7 10
for helium atmosphere
12
■ RESULTS AND DISCUSSION
To prepare the liposomal constructs, CrONO and mac-
CrONO were dissolved in phosphate buffer saline (PBS) at
pH 7.4 and the solution was used to dissolve a thin film of PC.
The mixture was freeze−thaw cycled and then extruded
through a liposome extruder to achieve constructs of
approximately 120−130 nm in diameter as determined through
dynamic light scattering (DLS). The unencapsulated CrONO
was removed from the liposomes through dialysis. These
constructs remain stable for a minimum of 2 weeks after
dialysis, as determined by DLS (see Supporting Information).
The ability for NO to escape the lipid membrane of liposome
encapsulated CrONO (Figure 1) was measured with an ami-
700 NO-specific electrode (Innovative Instruments) at 25 °C in
pH 7.4 PBS. A high-pressure mercury lamp attenuated with a
filter (λex >350 nm, I0 ∼ 1018 photons/s) was employed as the
light source. The CrONO complexes were successfully
activated through the liposomes photochemically as determined
through NO release (Figure 1). In contrast, no nitric oxide was
detected upon similar photolysis of liposome solutions
prepared without CrONO or from solutions of liposome
encapsulated CrONO that were not irradiated. This demon-
strated that the PC liposomes served as stable vessels for the
nitric oxide precursor and once the NO is uncaged photo-
chemically, it can readily diffuse across the lipid membrane.
The profile of NO released from the liposome-encapsulated
CrONO after photolysis is distinctly different from that of
unencapsulated CrONO. Unencapsulated CrONO shows an
initial burst of NO followed by a rapid decrease in
concentration despite continued irradiation. This is presumably
due to the complex photochemistry of CrONO in oxygenated
solutions where continued irradiation leads to formation of a
CrIV intermediate that can be oxidized by O2, leading to
generation of superoxide as well as NO.18 The superoxide
consequently scavenges NO, trapping it as peroxynitrite and
leading to the decrease in NO concentration detected by the
NO electrode, despite continued irradiation (see Scheme 1).18
This rapid decrease in NO concentration is not seen during
photolysis of the liposome-encapsulated CrONO. Instead a
nearly steady state is achieved where NO production is
balanced by depletion processes (autoxidation, diffusion, etc.)
with a very gradual decrease in concentration over time. This
could be due to the increased permeability of the membrane to
the NO gas as opposed to the CrONO itself or superoxide
generated after oxidation of the CrIV photoproduct. The
enhanced partitioning of NO across the lipid bilayer could
minimize scavenging of NO by the ionic superoxide inside the
liposome. Finally, the liposome itself could also act as a
reducing agent, reacting with the superoxide generated or
reducing the CrIV photoproduct to suppress superoxide
generation analogous to the use of glutathione (GSH) (Scheme
1). This shows that liposome encapsulation of the CrONO
complex can help facilitate controlled, steady release of NO
during photolysis in oxygenated solutions. This would be
critical for the application of CrONO as a therapeutic NO
delivery agent, where a constant, steady release of NO at a
specific concentration would be needed.
The quantitative release of NO by both the liposome
encapsulated and unencapsulated CrONO under oxygenated
and anoxic conditions was measured with a Sievers nitric oxide
analyzer 280i (NOA). As shown in Figure 2, unencapsulated
CrONO had a significant loss of net NO release in oxygenated
solutions compared to anoxic solutions, corresponding to >90%
loss of NO due to scavenging by superoxide. This dramatic loss
is not observed for liposome-encapsulated CrONO (Figure 3).
This supports our hypothesis suggesting that liposome
encapsulation enhances the overall NO release by reducing
the scavenging of NO by superoxide presumably due to the
differential partitioning of NO into liposome membrane or by
reaction of the PC with any generated photoproducts (CrIV,
superoxide). The quantum yields (QY) for net NO releases
were also determined for both unencapsulated and liposome-
Figure 1. Concentration of NO in solution as determined by a NO-
specific electrode for solutions containing liposome encapsulated
CrONO. The initial solution was 3 mL of 10 mM PBS at pH 7.4 and
was irradiated continually with visible light from a high pressure Hg
lamp (>350 band-pass filter, I0 ∼ 1018 photons/s). At ∼100 s a 200 μL
sample of the liposome solution was injected. The sample containing
CrONO showed a strong signal indicating NO generation (blue),
while the liposome solution without CrONO did not (black). The
same experiment in the dark did not show any NO production
(orange). The NO release is compared to that seen for unencapsulated
CrONO (200 μM) (green). Figure 2. Representative NOA trace showing the NO release after 5 s
irradiation at 436 nm with a Hg lamp (8.0 × 1015 photons/s) of 300
μM CrONO in anoxic (blue) and oxygenated (orange) conditions in
15 mM phosphate buffer pH 7.4 at 25 °C. The integrated area is
proportional to the amount of NO released, where moles of NO =
area/6.8 × 1012 in air and moles of NO = area/5.7 × 1012 in He.
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encapsulated CrONO and are shown in Table 1 (individual
values with statistical analysis are shown in Table S1 and Table
S3 in the Supporting Information). The QY for net NO release
in oxygenated environments is much greater for the liposome-
encapsulated CrONO (0.04 ± 0.01) compared to unencapsu-
lated CrONO (0.006). It should be noted that, for
unencapsulated CrONO in oxygenated environments, the
NO release rapidly decreases during continuous irradiation,
however this is not the case with the liposome-encapsulated
CrONO sample (Table S2 in the Supporting Information).
This shows that the liposome not only functions as a stable
container for delivery of CrONO cargos but also enhances the
rate and yield of effective NO released in oxygenated
environments.
Another NO precursor we have previously described is the
anthracene-labeled CrONO analogue,17 trans-Cr(mac)-
(ONO)2
+ (mac = 5,7-dimethyl-6-anthracenyl-cyclam, mac-
CrONO structure shown in the Supporting Information).
The dye pendant to the CrONO moiety may have several
functions. One is that when exciting with higher energy light it
serves as an antenna to collect light and to sensitize
photoreactions of the CrIII complex, thus enhancing the
amount of NO released.16 By using an appropriate pendant
dye, the NO release can be sensitized to occur after two-photon
excitation with lower-energy light, allowing for greater tissue
penetration for in vivo NO release.19 Another function of the
dye is that the anthracenyl fluorescence (see Supporting
Information Figures S1 and S2) serves as a luminescent marker
for the CrONO complex. While the sensitization can lead to
more NO release, it is accomplished only by excitation with UV
light that may be toxic to certain cell types.36 For these studies
mac was employed solely as a luminescent marker for the
CrONO, and NO release was triggered with lower-energy blue
light. In this context, PC liposomes were prepared using
identical procedures to encapsulate CrONO and mac-CrONO
from trans-[Cr(cyclam)(ONO)2]BF4 and trans-[Cr(mac)-
(ONO)2]BF4, respectively.
Fluorescence measurements determined that the emission of
the mac ligand was measurable across the lipid membrane
(Figure S2 in the Supporting Information) although the light
scattering from the liposomes lowered the intensity of the
fluorescent signal. The NO released upon photolysis of the
encapsulated mac-CrONO was quantitatively analyzed using a
Sievers nitric oxide analyzer 280i (NOA). The samples were
photolyzed for 30 s with a blue (470 nm) light emitting diode
(Thor Laboratories), a low-intensity, portable light that has
proved applicable for CrONO photolysis for in vitro experi-
ments (for example porcine arterial vasorelaxation).17 In this
measurement, the integrated signal defines the amount of NO
released. The results are shown in Figure 4.
As shown in Figure 4, even with a low-intensity visible (blue,
470 nm, 1.7 × 1015 photons/s) LED light source there is
significant NO released during the 30 s photolysis of the
encapsulated mac-CrONO. The amount of encapsulated mac-
CrONO was quantitated by detection of the total NO released
(Figure S8 in the Supporting Information). Assuming that two
NOs were released by each complex as shown previously in this
laboratory,18 this result corresponds to a concentration of
roughly 15 μM of mac-CrONO in the liposome sample. This is
in agreement with the measured concentration determined by
absorbance, where the solution would be 16.3 μM (see
Supporting Information).
The quantum yield for NO release from mac-CrONO inside
the liposomes was also determined in both oxygenated and
anoxic conditions as for CrONO (Table 1). Again, a larger QY
Figure 3. Representative NOA trace showing the NO release after 30 s
irradiation with a blue LED (470 nm, 1.7 × 1015 photons/s) of 300 μL
aliquot of CrONO in liposomes in anoxic (blue) and oxygenated
(orange) conditions in 10 mM PBS at pH 7.4, 25 °C. The integrated
area is proportional to the amount of NO released, where moles of
NO = area/6.8 × 1012 in air and moles of NO = area/5.7 × 1012 in He.
Table 1. Comparison of QY for NO Release from Liposome-
Encapsulated CrONO and mac-CrONO in Both Oxygenated
and Anoxic Solutions
aDetermined at I0 = 1.7 × 10
15 photons/s, 470 nm LED irradiation.
bDetermined at I0 = 8.0 × 10
15 photons/s, 436 nm irradiation, ref 15.
cDetermined at I0 = ∼1015 photons/s, using absorbance changes, 436
nm irradiation. See ref 16. dDetermined at I0 = 4.0 × 10
15 photons/s
436 nm irradiation. The QY is changing rapidly under these
conditions, see ref 17 and Table S2 in the Supporting Information.
The value reported is the highest value determined.
Figure 4. NOA trace showing the NO release after 30 s irradiation by
a blue LED (470 nm, 1.7 × 1015 photons/s) with helium bubbling in
10 mM PBS pH 7.4 at 25 °C: black, liposomes without any NO
precursor; blue, liposome encapsulated mac-CrONO (2.7 μM). The
integrated area is proportional to the amount of NO released where
moles of NO = area/5.7 × 1012.
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(0.04 ± 0.01) is determined for net NO release in oxygenated
buffer solutions from the liposome-encapsulated mac-CrONO
sample compared to the unencapsulated CrONO complex in
solution (0.006), showing that the encapsulation of the NO-
releasing complex can help facilitate controlled, steady release
of NO across the liposome membrane. The amount of NO
released during the photolysis of such liposome constructs
using the low-intensity blue LED light corresponds to 1−10
nM concentrations of NO in solution, depending on the
duration of irradiation (10−30 s). This is on the order of what
is needed for therapeutic NO delivery, as it is nM
concentrations that will activate soluble guanylyl cyclase, a
primary pathway in bioregulation by NO.37
In summary, these studies have demonstrated that the
photochemical NO precursors CrONO and mac-CrONO can
be encapsulated into stable phosphatidylcholine liposomes and
that photolysis of these in solution is an effective method for
delivering NO. Liposomes are particularly attractive for use
during therapeutic delivery of NO, as they allow for a
controlled and steady release of NO as compared to CrONO
free in solution, especially in oxygenated solutions. In addition,
the modularity of self-assembly affords the ability to tune the
mechanical properties of liposomes through chemistry30 and in
vivo functionality through the incorporation of biomole-
cules.21,26−29,38
Furthermore, the encapsulation of both fluorescently labeled
and NO releasing complexes, such as mac-CrONO, results in
theranostic constructs that are effective as both a diagnostic and
therapeutic agent. This work provides some fundamental
insight for the development of self-assembled multifunctional
liposome constructs for disease theranostics.
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